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INTRODUCTION
C
ombination therapy that includes inhibitors of HIV-1
protease (HIVp) are necessary to treat HIV-infected
patients.1 Currently, there are eight peptidic and two
nonpeptidic drugs on the market that competitively
bind in the active site and inhibit HIVp by mimick-
ing substrates and the transition state of peptide cleavage.2
The discovery of novel inhibitors is still a very active area of
research due to the associated toxicity, poor pharmacokinetic
properties, and resistance that has developed to the existing
drugs.
HIVp is a C2-symmetric dimer with its active site located
at the dimer interface. The central active site is covered by
two glycine-rich, antiparallel b-hairpins, referred to as the
‘‘flaps’’ (residues 43–58). The conformational behavior of the
flap region has been extensively studied.3 The largest popu-
lated states are thought to be closed, semiopen, and open.
The semiopen conformation is the most prevalent in the apo
state, and the closed state is seen when competitive inhibitors
are bound in the active site. Two groups have used Langevin
Dynamics (LD) simulations to demonstrate the extensive
conformational sampling available to the flaps in the apo
state.4,5 Upon introduction of a ligand into the active site of
a semiopen conformation, LD simulations have shown that
the ligand will induce the flaps to close and replicate key
hydrogen bonds seen in bound crystal structures.6,7
Here, we present a novel mode of action for HIVp inhibi-
tors: modulating the conformation behavior of HIVp by tar-
geting the flap-recognition site. Upon substrate binding, each
flap closes down and positions its flap tip (residues 49–52) in
a highly conserved region on the opposite-side monomer, see
Figure 1a. This region can also be called the ‘‘eye’’ from recent
HIVp naming convention (based on the backbone of the
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dimer resembling the face of a bulldog). When the flaps close
over the active site, there is a 5–7 Å shift from the apo form
and an inward rotation of each monomer. Also, the ‘‘handedness’’
of the orientation of the flap tips reverses upon closing.4–8
The flap-recognition site may play a role in the opening of
HIVp. Substrate proteins can only access the active site through
the open conformation,9 although the mechanism allowing
such entry is still under investigation.10 It has been proposed
that curling of the flap tips creates a ‘‘hydrophobic cluster’’ that
induces flap opening.11 This curling mechanism creates hydro-
phobic contacts between the flap tips and the flap-recognition
pocket residues on the same monomer; it has been observed in
simulations of flap opening by many groups.6,12,13
Targeting the eye site has interesting ramifications for
both the closed and open states. If the flaps cannot properly
close and coordinate the substrate, the catalytic efficiency of
HIVp drops.12,14–16 If the curling of the hydrophobic flap
tips into the eye site drives the conformational change into
the fully open state,5,11–13,16 then blocking the interaction
may interfere with its ability to open and bind its large sub-
strate. If either—or both—mechanisms are possible, an in-
hibitor bound to this site would alter the conformational
equilibrium of the system. It has been suggested that flap
dynamics plays a major role in the association and disassoci-
ation of substrates,13,17 and modulating the conformational
behavior of the flaps may be a potential mechanism for elud-
ing inhibitor resistance. Furthermore, the reduced binding
affinity observed for escape mutants of HIVp has been linked
to changes in the flexibility of the system.16,18
In this study, we show that a small molecule can be stably
bound in the flap-recognition pocket and prevent the flaps
from assuming the proper closed conformation. Using sol-
vent mapping to identify binding ‘‘hotspots,’’ we generated a
receptor-based pharmacophore model of the eye based on an
ensemble of conformations from the semiopen, apo state of
HIVp. Our use of ensembles of conformational states is
called the Multiple Protein Structure (MPS) method, and the
goal of the approach is to identify complementary interac-
tions that are well conserved over the ensemble.19–22 Those
essential interactions define a pharmacophore model used in
virtual screening to identify molecules with a potential
entropic advantage. A modest database of compounds was
screened to identify a small set of lead-like molecules that
complemented the MPS model. Because inhibition of the site
is unprecedented, a representative molecule was chosen for
dynamics simulations to examine the stability of the bound
complex before investing in experimental testing. Five inde-
pendent LD simulations were run for 5 ns each (total of 25 ns
of simulation time), and a molecular dynamics (MD) simu-
lation was also conducted for 10 ns. The dynamic simula-
tions revealed remarkable insights into the stability of the
bound inhibitor and its ability to control the flaps. The in-
hibitory activity of our compound was subsequently con-
firmed through experimental testing. This finding is the first
new inhibitor class for HIVp since the dimerization inhibi-
tors were introduced 17 years ago.23,24 No dimerization
inhibitors have been tested in the clinic, and all commercial
therapies are competitive inhibitors that bind within the
FIGURE 1 (a) When a monomer closes, it places its flap tips within the flap-recognition site of
the other monomer. The right monomer (gray with surface) is the apo, semi-open state that shows
the pre-existence of the site. The left monomer (yellow) is in the bound, closed state. I50 and G51
are shown in stick representation in direct contact with the ‘‘eye’’. (b) The individual residues within
the new eye site are each colored individually and labeled to show their placement within the cleft.
G78 and V56 are not visible in this view.
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central active site. Other potential allosteric sites on HIVp
have been proposed,3,13,25 but no inhibitors have been identified.
RESULTS
The MPS Pharmacophore Model
The eye site is primarily hydrophobic in character, which is
fitting given its role in recognizing the hydrophobic residues
of a flap tip. The lower portion of the cleft is defined by V32,
G78-P81, and I84 while the upper portion is defined by I47-
I50, I54, and V56 (Figure 1b). More distal contacts may be
possible with V82 and the backbone atoms of L33, K55, and
V77. Six of the twelve residues that define the flap-recogni-
tion pocket, G49, V56, G78, P79, T80, and P81, are highly
conserved.26,27 In fact, mutations to the invariant residue
T80 are detrimental to enzyme activity, and it is hypothesized
that this may be due to altered flexibility of the flap region.28
The other six residues, V32, I47, G48, I50, I54, and I84, are
known to mutate to residues that confer drug resistance to
existing protease inhibitors.26,27 Four of the six common
drug-resistant variants, V32I, I47V/A, G48V, and I50V/L,
maintain their nonpolar nature in the mutant form. I54 and
I84 have been shown to mutate to a variety of residues,
although the most common mutations are also hydrophobic,
I54V and I84V/A.
An ensemble of semiopen conformations was available
from our previous MD simulations of apo HIVp,20 and these
were used to create an MPS pharmacophore model of the eye
site, see Figure 2. The MPS model has seven sites. Three aro-
matic and two hydrophobic features complement the domi-
nant hydrophobic nature of the cleft. Hydrophobic elements
at the bottom of the eye cleft reflect the side chain of I500,
except that the elements show that it might be possible to
make slightly deeper interactions within the cleft. A hydrogen-
bond donor element complements the backbone carbonyl
oxygen of G48, and a hydrogen-bond acceptor complements
the backbone amine of I50. The hydrogen-bond acceptor ele-
ment perfectly reproduces the backbone interaction provided
by G510, the flap tip from the opposite monomer found in
the eye site of bound crystal structures.
The MPS model was screened against a modest set of
34k compounds using MOE. Requiring six of seven phar-
macophore elements to be matched, 11 compounds were
identified with a molecular weight of  300 Da. The eye cleft
is small, and we chose a small size cutoff to avoid any false
leads resulting from large, greasy compounds binding in a
traditional fashion to the central active site. Compound 1
(2,2,4-trimethyl-1,2-dihydroquinolin-6-yl benzoate) was
chosen as the representative inhibitor for dynamics simula-
tions because it had the fewest rotatable bonds and best com-
plemented the bend of the cleft, see Figure 2. Furthermore,
the features of 1 were the closest match to all seven elements.
Though it only matches six of the seven features, the conju-
gated nature of its bicyclic ring is a close approximation of
the two closely spaced aromatic features.
The molecules identified for binding in the eye cleft are
significantly smaller than existing inhibitors (the other 10
identified compounds are shown in Supporting Information).
The molecular weight range for the protease inhibitors cur-
rently on the market is 505–720 Da, but 1 has a molecular
weight of 293 Da. Smaller molecules generally have better
pharmacokinetic properties, and these entities could have a
FIGURE 2 (a) MPS pharmacophore model mapping the eye region of the semi-open conforma-
tion. Elements are color-coded according to chemical functionality: red for hydrogen-bond donor,
blue for hydrogen-bond acceptor, cyan for hydrophobic, and green for aromatic. (b) Close-up view
of model with a 908 rotation as in Fig 1b. Compound 1 (2,2,4-trimethyl-1,2-dihydroquinolin-6-yl
benzoate), identified through the virtual screen, is shown overlaid with MPS pharmacophore model
to demonstrate the agreement between its chemical scaffold and the pharmacophore elements.
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significant advantage in clinical use over existing HIVp inhib-
itors. Furthermore, both potential hydrogen bonds are
formed with backbone atoms of the protease which may be
advantageous for overcoming potential escape mutants. In
fact, the co-crystal structure of darunavir, a recently approved
nonpeptidic inhibitor, demonstrated key hydrogen bonds to
the backbone of both monomers of HIVp29,30; darunavir
exhibits exceptional broad-spectrum activity against a large
panel of MDR HIV-1 strains.30 Though the sites of hydrogen
bonding in the eye are not the same as those between daruna-
vir and HIVp, it shows that targeting the backbone is a feasi-
ble way to counteract resistance mutations.
LD Simulations of Compound 1 in the ‘‘Eye’’
Analysis of the LD simulations confirmed the stability of the
complex. During four of the five simulations, compound 1
continued to interact in a stable fashion with the residues of
the flap-recognition pocket as demonstrated by Figure 3a.
However, 1 was seen to temporarily dissociate and rebind to
the eye site. For example, during Run 1 (blue trajectory) at
1.3 ns, compound 1 disassociated from the eye pocket into
the solvent but returned to its original binding pose after 500
ps. However, the behavior of 1 during Run 2 (purple trajec-
tory) was the most intriguing. At 2 ns, compound 1 disasso-
ciated from the pocket and into the central active site. Over
the following nanosecond, it traversed the active site and
associated into the flap-recognition pocket of the opposite side
monomer, assuming the initial binding pose in the other eye
site, Figures 3b and 3c (additional snapshots are provided in
Supporting Information). After 100 ps, 1 flipped 1808 and
maintained this pose for the duration of the simulation.
Docking studies with AutoDock 331 also predicted both
binding modes (data not shown); hence, it may be possible
for 1 to adopt both poses. Figures 3b and 3c shows snapshots
of the transition of 2–3 ns in Run 2. Though the handedness
of the flap remain the same, the packing shifts with the trans-
location of the compound.
The effect of bound compound 1 on the dynamics of the
protease was also characterized. The LD simulations were
chosen to provide a great deal of conformational variation.
Figure 4a reveals representative conformations sampled over
Run 3 (conformations from all five LD simulations are pro-
vided in the Supporting Information). It is very encouraging
to see that compound 1 can complement the eye site in many
FIGURE 3 (a) The stability of compound 1 in the eye site is dem-
onstrated by the RMSD to its starting position. Each of the five in-
dependent LD is given. Several events are seen where the ligand dis-
sociates and rebinds again in the same pocket (temporary spikes up
to 10 Å). In the second simulation (purple line), 1 starts in the flap-
recognition pocket of one monomer, disassociates into the central
active site, then binds in the eye site of the other monomer. (b) Rep-
resentative structures from 2–3 ns of Run 2 show the migration. An
early snapshot is shown with a blue backbone and yellow inhibitor;
a late structure is shown with a red backbone and gray inhibitor.
The transparent inhibitors in the central pocket are actual positions
sampled during the migration. (c) A close-up, top view of the flap
region shows how the flap tips pack against the inhibitor. The hand-
edness stays the same, but the packing shifts from right (blue) to left
(red) with the migration of compound 1.
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conformations. This is likely the result of our MPS models
incorporating the behavior of the protein across an ensemble
of conformational states and may yield an entropic benefit.
The flaps of the protease widely sampled about the semi-
open state during LD (Figure 4a); to quantify the vertical
movement of the flaps, the distance between the flap-tip resi-
due I50 and the catalytic residue D25 was calculated for each
monomer. In the 1HHP crystal structure of the apo form,
the distance is 17.2 Å. The distance averaged 19 Å varied
between 15 and 25 Å over the simulations (Supporting Infor-
mation). The monomer with 1 bound was slightly more sta-
ble than the opposite monomer (the standard deviation for
its I50-D25 distance was 2 Å, as opposed to 3 Å for I500-
D250). Furthermore, the flap of the opposite, unbound
monomer frequently sampled a ‘‘collapsed’’ conformation
(I500-D250  14.1 Å, which is the distance seen in closed con-
formations). Figure 3c shows additional asymmetry across
the flaps, occurring when the flap tips associate. Over the
course of the sampling, contact between the flaps was fre-
quently observed, and correlated dynamics analysis clearly
showed frequent, ordered motion between the flap tips
(Figures 4b and 4c). The transient organization between the
flap tips was intriguing, especially given the large flexibility
seen in the simulations. We turned to explicit-solvent MD
simulations to more accurately model the system. The use of
explicit water allows for a more accurate representation of
solvation and its ability to drive hydrophobic association.
Molecular Dynamics Simulations of
Compound 1 in the ‘‘Eye’’
Compound 1 remained bound in the flap-recognition pocket
in a stable fashion. At the beginning of the simulation, it dis-
associated into the solvent but, after only 250 ps, returned to
the eye pocket in its initial binding pose. After this, a consist-
ent binding pose was maintained; the root mean square devi-
ation (RMSD) was 1.7 6 0.5 Å (the average position of 1 over
the MD simulation was used as a reference state). The 1,2-
dihydroquinoline core remained in a stable position while the
benzoate moiety flipped throughout the simulation.
It was surprising to find that the explicit water promoted
a closed form of HIVp (see Figure 5). It is important to stress
that the system was initiated from a complex with HIVp in
the semiopen, apo form. The complex was fixed while the
water was equilibrated around it, so the initial setup of the
water did not force an inappropriate collapse of the pro-
FIGURE 4 (a) Overlay of snapshots taken every 0.5 ns across the
third LD simulation. A large degree of sampling is seen in the flap
region. (b) However, some order is apparent in the correlated dy-
namics (strong positive correlations are in red and yellow, pro-
nounced anti-correlated motion is dark blue). Over the entire simu-
lation, the strongest positive correlations between the monomers
(upper left and lower right regions) are the flap tips (noted white
circles) and the C-terminal b-sheets that comprise much of the
dimer interface (marked with white triangles). (c) The strength of
the correlation between the flaps varies over the course of the simu-
lation, periodically showing very strong correlations. The periods of
strong coupling lasted a maximum of 1.75 ns in Run 1, 1.25 ns in
Run 2, and 2.5 ns in Runs 3–5.
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tein.32 It occurred over the last 300 ps of equilibration where
the protein was finally allowed to relax. A smaller degree of
continued relaxation can be seen in the RMSD of the system
over the first 2 ns (Supporting Information).
How is the protease able to assume a closed conformation
with 1 bound in the flap-recognition pocket? Blocking the
eye should prevent the flaps from closing. Careful examina-
tion revealed that this is an alternative closed state, not the
same state seen in bound crystal structures of HIVp.8 It is well
established that the orientation of the flaps reverses in going
from the apo state to the closed form,4–7 but the presence of
1 in the eye prevents the flaps from properly folding down.
Instead, they form an alternative closed state that maintains
the ‘‘handedness’’ of the apo form (see Figure 5). The flaps
do not change orientation, so the tips do not occupy the
other monomer’s flap-recognition pockets. It is very likely
that this state could render HIVp inactive as the substrate
will not be properly complemented for cleavage.
The distances between the flap-tip residues I50/I500 and
D25/D250 at the bottom of the pocket were calculated for
each monomer (Supporting Information). As implied in the
LD simulations, the monomer with 1 bound remained
slightly more open than the ligand-free flap; respectively, the
distances averaged 14.5 6 0.9 Å and 12.8 6 0.8 Å for the
flaps in the MD simulation. To provide a reference, the dis-
tances in the bound crystal structure 1PRO are 14.1 Å. It
appears that the flap with 1 is ‘‘closed’’ and the opposite flap
is even more closed. As seen in Run 2 of the LD simulations,
the presence of 1 creates an asymmetry between the flaps. To
further characterize the asymmetry, the distance between flap
tip residue G51/510 and the eye pocket residue T80/800 was
calculated (Supporting Information). The average distance
for the monomer with 1 bound is 12.4 Å, but it is 10.6 Å for
the ligand-free monomer. The ‘‘collapse’’ of the ligand-free
monomer promotes the alternative closed form by stabilizing
the opposite flap in accommodating the binding of com-
pound 1. In fact, when a second ligand is introduced into the
system (i.e., one compound in the eye pocket of each mono-
mer in the semiopen state), the complex is not stable (data
not shown). The stoichiometry of one compound per mono-
mer may not be possible due to lack of space on the ligand-
free side.
Experimental Verification of Predicted Compounds
Given the simulation data to support the stability of the
complexes and the promotion of an alternative closed state,
experimental testing was pursued. Compound 1 was found
to be auto-fluorescent and could not be evaluated in our
FRET-based assay.33,34 As such, a para-methoxy derivative
(compound 2: 2,2,4-trimethyl-1,2-dihydroquinolin-6-yl 4-
methoxybenzoate) was chosen for testing. The compound
also fits the MPS pharmacophore model, but slightly
exceeded the 300 MW cutoff. Compound 2 was shown to in-
hibit HIVp; the IC50 value was determined to be 18 6 3 lM,
FIGURE 5 The average structure from the 10-ns MD simulation is shown in yellow; compound
1 is colored by atom type. The semi-open, apo form is shown in blue, and the closed, bound form
is shown in red (co-crystallized inhibitor in the central pocket is not shown for clarity). The MD
samples a closed conformation that differs from traditional bound crystal structures. The flaps are
lowered, as is appropriate for a closed structure, but the elbows are displaced slightly outward as in
the apo state. The handedness of the flaps matches the apo state, not the bound state.
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shown in Figure 6. The binding affinity is modest but falls
within the range of a lead-like compound, as does the molec-
ular weight.35–37 Oprea et al. noted that lead-like guidelines,
not drug-like profiles, should be followed in initial phases of
drug discovery to filter compounds.36,38 If drug-like rules
were employed, the identified lead compounds may be diffi-
cult to optimize while remaining in drug-like space.39
DISCUSSION
Finding novel mechanisms to inhibit HIVp is very important
to overcome the resistance associated with current inhibitors
and improving pharmacokinetic properties. We have shown
in this study that the flap-recognition pocket can accommo-
date small molecules and remain stable across multiple LD
trajectories. Furthermore, the inhibition activity of 2, a simple
derivative of our modeled lead compound, was experimen-
tally verified (IC50 5 18 lM). These inhibitors are much
smaller than existing protease inhibitors and chemically very
distinct. They are nonpeptidic and do not contain the usual
hydrogen-bonding features of traditional inhibitors (keto-
amides, alcohols, vinyl sulfones, etc). Hence, there is little
likelihood that they are acting as traditional competitive
inhibitors within the enzymatic binding site of HIVp. In fact,
modeling showed that 1 is not stable within the central
pocket; instead, it will migrate to the new site and form an
appropriate complex.
Further clarification of the mechanism of inhibition by
enzymatic assay is not possible because allosteric regulators
that bind to apo states of proteins exhibit kinetics that are
the same as competitive inhibitors. If the inhibitor regulates
the flaps, it will reduce the binding of competitive inhibitors
in a cross-competition assay, and the kinetics would appear
the same as two traditional inhibitors competing for the
active site. Structural studies are underway to definitively
determine the binding of 2 and its mechanism of action.
The presence of a ligand in the flap-recognition pocket
appears to alter the conformational behavior of the flap
region, which may directly modify the kinetics of the system.
We hypothesize two inhibition mechanisms: (A) an inhibitor
may bind in the flap-recognition pocket and the resulting
altered conformation prevents the substrate’s access to the
active site or (B) the substrate may bind concurrently with
the inhibitor, but substrate cleavage cannot occur because
the flaps cannot close with the eye occupied. Furthermore, if
the flap-tip curling hypothesis is correct, the flaps of HIVp
may not be able to sample an open conformation when the
inhibitor is bound.
There are several reasons why this new site is so attractive.
First, crystal structures show flap recognition is essential in
forming the closed conformer. As previously mentioned, if
the flaps cannot close appropriately, the substrate is not
properly positioned for cleavage. Second, half of the residues
defining the eye pocket are highly conserved and may be re-
sistant to escape mutation. Those that do mutate maintain
the hydrophobic character which appears to drive the associ-
ation of our inhibitor. Third, this site is much smaller than
the central cavity, so it may yield inhibitors with low molecu-
lar weight which could have better pharmacokinetic proper-
ties than current HIVp drugs. Fourth, if effective, the new
entities could be added to formulations of existing inhibitors
as a combination therapy. Lastly, enhanced affinity should be
accessible. We stress that no optimization has yet been
attempted with this inhibitor class.
This study presents a new mode of inhibition of a key
therapeutic target. In fact, this may be the first new mecha-
nism of action in 17 years.23,24 Targeting the elbow (resi-
dues 39–42) and b-sheet region (residues 1–5 and 95–99)
have been proposed in the literature as potential inhibition
mechanisms,3 but no actual inhibitors have been identified.
The dimerization inhibitors are the only experimentally veri-
fied alternative therapies to competitive, active-site inhibi-
tors, but none have made it to the clinic.
FIGURE 6 Compound 2 is a para-methoxy derivative: 2,2,4-tri-
methyl-1,2-dihydroquinolin-6-yl 4-methoxybenzoate. Its IC50 was
measured to be 18 6 3 lM. The activity of HIVp was monitored
using a FRET-based assay; upon cleavage of the quenched peptide
substrate, fluorescence is recovered. Inhibition is measured as a
result of the time-dependent decrease of fluorescence intensity that
is linearly related to substrate cleavage. Pepstatin A is shown as a
control (IC50 5 3.8 6 0.5 lM under the assay conditions used).
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MATERIALS AND METHODS
Multiple Protein Structures Method
Previously,21 our group conducted independent, 3-ns MD simula-
tions of three unbound structures of HIVp (1HHP,40 3HVP,41 and
3PHV42). MPS from those simulations were used to generate a re-
ceptor-based pharmacophore model. Snapshots were taken after
equilibration and every 600 ps along each 3-ns MD trajectory; each
monomer was considered a separate structure, resulting in a collec-
tion of 36 conformations from a total of 9 ns of simulation time. In
our aforementioned work,20,21 we focused on mapping the bottom
of the central cavity to describe the complementarity of competitive
inhibitors. In fact, any features of the solvent mapping that were far-
ther 9 Å from the catalytic acids were ignored; these included probes
that occasionally minimized to the eye site.
For this study, the flap—particularly the eye region—was the
focus. The base of the flap in each structure was flooded with 500
small molecule probes (benzene, ethane, and methanol). Each struc-
ture was then subjected to a multiunit search for interacting con-
formers (MUSIC) simulation with the BOSS program,43 using the
OPLS force field,44 while the protein was held rigid. This resulted in
clusters of small molecule probes at favorable interaction mimima
within the eye site of HIVp. Probes were clustered using an in-house
program based on Jarvis-Patrick methodology. If 8 probes appeared
in a cluster, it was considered significant and included in the con-
sensus step below. For that step, each cluster was represented by its
‘‘parent,’’ the probe with the most favorable interactions with the
protein.
‘‘Consensus clusters’’ were determined by aligning the protein
snapshots with the equilibrated 1HHP structure and identifying
interactions (positions of parent probes) that were common over
50% of the MPS. Each consensus cluster was then represented in
the pharmacophore model as a spherical element. The center of
each element was defined by the average position of the probe mole-
cules (benzene centroid, the midpoint of the carbon–carbon bond
for ethane, and the oxygen atom of the methanol probe). The radius
was based on the RMSD of those features. Individual benzene clus-
ters were labeled aromatic elements whereas ethane clusters were
termed hydrophobic. Methanol clusters were classified as a hydro-
gen-bond donor or acceptor element, based on their interaction
with the protein surface. This procedure resulted in a seven-site
pharmacophore model of the eye region; the model coordinates are
provided in the Supporting Information. Full details of the MPS
method can be found elsewhere.20,45
Virtual Screening
The MPS pharmacophore model was screened against a virtual
dataset (33,623 molecules) based on a subset of compounds avail-
able from the University of Michigan’s Center for Chemical
Genomics. The dataset was screened using the search option within
the Pharmacophore Query Editor of MOE.46 Multiple conforma-
tions of each ligand were pre-generated using the default parameters
of OMEGA47 with the exception of the energy window and RMS
threshold set to 14 kcal/mol and 1, respectively; the maximum num-
ber of conformations was 300. During the database search, a com-
pound was required to fulfill six of the seven features to count as a
hit, and the radii of the elements were set to 1.33 RMSD. This pro-
duced small, tractable numbers of compounds that were strictly
held to the pharmacophore features. The eye model identified 11
compounds within a 300 Da molecular weight filter. The predicted
poses were manually viewed to verify complementarity and appro-
priate overlap with the pharmacophore model. Compound 1 was
chosen as a model compound for the theoretical simulations
because it best complemented the features of the model as described
above. The structures of all 11 identified compounds are provided
in the Supporting Information.
Dynamics Simulations
Unrestrained, all-atom MD and LD simulations were conducted
with AMBER848 and the FF99SB force field.49 The MD simulation
used explicit solvation with TIP3P water50 while aqueous solvation
was implicitly modeled using the Generalized Born approach51 for
the LD simulations. Simulations were initiated from the crystallo-
graphic coordinates of the apo monomer of HIVp obtained from
the PDB52 (PDB ID: 1HHP40), and the homodimer was generated
using C2 symmetry operations in PyMOL.
53 Hydrogens were added
via the tLEaP module. MD and LD simulations were performed
using the 1HHP dimer in complex with a single copy of compound
1 in eye site of one monomer. The starting coordinates for 1 were
obtained from the binding pose generated in the MOE pharmaco-
phore screen. The Antechamber module with the GAFF54 force field
and AM1-BCC charges55 was used to determine force field parame-
ters for 1.
Explicit-solvent, MD simulations were performed for 10 ns using
one random-number seed. The hydrogen atoms were first mini-
mized, and then the system was solvated using truncated octahedral
boundary conditions with a buffer distance of 12 Å and closeness
parameter of 0.5. The 14e charge of HIVp was neutralized by the
addition of four chloride counter ions placed 10 Å from the protein
surface in the most electropositive regions. The simulation was run
in the NPT ensemble, and SHAKE was used to constrain all bonds
to hydrogen atoms. A 2 fs time step was used, along with a 10 Å cut-
off for nonbonded interactions and particle mesh Ewald for long-
range electrostatics. For the solvated system, the hydrogen atoms
were first minimized, followed by side chains, and lastly all atoms.
The system was equilibrated in a series of four stages: a gradual
heating of water from 10 to 310 K over 50 ps, followed by water
equilibration with protein restrained for 250 ps at 310 K, then a full
system heating from 10 to 310 K over 50 ps, and finally, full system
equilibration with the protein unrestrained at 310 K for 250 ps. The
production phase was run for 10 ns at 310 K.
Five independent LD simulations of HIVp in complex with 1
were run for 5 ns starting from different random-number seeds.
Each simulation was run using a 999 Å cutoff for non-bonded inter-
actions. Default dielectric values were used: interior 5 1 and exte-
rior 5 78.5. The hydrogen atoms were first minimized, followed by
a minimization of all atoms. The system was equilibrated over a se-
ries of six steps; the first three equilibration steps were each per-
formed for 10 ps, steps four and five over 50 ps, and the sixth step
for 100 ps. During the first two equilibration steps, the system was
gradually heated from 100 to 300 K and remained at 300 K for the
subsequent steps. Restraints were placed on all heavy atoms and
gradually removed over the first four equilibration steps using force
constants from 2.0 to 0.1 kcal/mol  Å2. Throughout the fifth equilib-
ration step, the backbone atoms remained restrained with a force
650 Damm et al.
Biopolymers
constant of 0.1 kcal/mol  Å2. In the sixth, and final, phase of equili-
bration, all force restraints were removed, and the system was run
for 100 ps at 300 K. The subsequent production phase was run for
5 ns. A time step of 1 fs and 1 ps21 collision frequency was used and
SHAKE was employed to constraint hydrogens. This protocol is
based on that used by Simmerling and coworkers for HIVp.4,7
The correlated dynamics were calculated using the ptraj module,
augmented with in-house scripts for visualization and parsing sub-
sets of data. Analyses of the flap conformation and ligand position
were also performed with ptraj. The MD trajectory was aligned to
its average structure across the 10 ns simulation. However, for LD
each trajectory was aligned to the fully minimized 1HHP, the last
common structure between the simulations. RMSD traces were cal-
culated for 1 versus its initial position within the eye region. The
following metrics were used to quantify the movement of the flaps:
the distance between flap tips and catalytic acid (I50 to D25 and
I500 to D250) and the distance between flap tips and eye pocket
(G51 to T80 and G510 to T800). Ca atoms were used to measure dis-
tance between residues.
HIV-1 Protease Inhibition Assay
A FRET-based assay was available, but unfortunately compound 1
was auto-fluorescent and could not be assayed. However, a para-
methoxy derivative of 1 (compound 2) was available to experimen-
tally test the chemical class. The employed assay is based on a previ-
ously described procedure for HIVp.33,34 The substrate used in the
assay is an oligopeptide, RE(EDANS)SQNYPIVQK(DABCYL)R,
purchased from Molecular Probes (Cat. No. H-2930). Compounds
1 and 2 were purchased from Chembridge. HIVp was purchased
from Bachem Biosciences (Product H-9040). Pepstatin A was pur-
chased from USB (lot No. 110018) and employed as a control.
Fluorimetric assays were performed, in triplicate, in 384 well
plates (Corning No. 3676) and read using a SpectraMax M5 from
Molecular Devices. The excitation/emission wavelengths of the sub-
strate are 340/490 nm and employed a cutoff filter at 475 nm. PEG-
400 was diluted in Buffer A (20 mM phosphate, 1 mM DTT, 1 mM
EDTA, 20% glycerol and 0.1% CHAPS at pH 5.1), and 1 lL was
added to each well (PEG-400 final concentration, 0.1%) to counter
HIVp precipitation, increase solubility of compounds, and prevent
aggregation as a false positive. Each compound was dissolved in
dimethylsulfoxide (DMSO) then diluted in water, and 2 lL was
added to each well to provide a final concentration range of 1–78
lM for the compound and 1.25–1.87% for DMSO. This was fol-
lowed by 5 lL of the protease diluted in Buffer A (final concentration
of 30 nM). After 45 min of incubation at room temperature, 12 lL
of substrate (diluted in Buffer A, final concentration 2 lM) was
introduced to initiate the assay, and the fluorescence monitored for
5 min. Given that the concentration of the enzyme is much less than
the inhibitor, Ki can be approximated as IC50/(11[S]/KM). The con-
centration of substrate, [S], is much less than its Michaelis constant
KM, previously determined to be 103 6 8 lM.
33 This makes IC50
measured under our conditions a good estimate of Ki, assuming the
enzyme kinetics are appropriate with this new mode of inhibition
(they are appropriate for both competitive and allosteric inhibition).
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